Drug Profile
AMG 224
Alternative Names: AMG-224Latest Information Update: 24 Oct 2022
Price :
$50
*
At a glance
- Originator Amgen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 22 Apr 2022 Amgen completes a phase I trial for Multiple myeloma (Second-line therapy or greater) in USA (NCT02561962)
- 28 Dec 2018 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in Australia (IV)
- 01 Nov 2015 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in Australia (IV)